FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Peter Collins

Research Profile

Living Beings

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Ruth A Karron; Elizabeth Schappell; Bhagvanji Thumar; Ursula J Buchholz; Peter L Collins
Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines.
John Tregoning; Belinda Lei Wang; Yuko Yamaguchi; Alexander Bukreyev; Peter L Collins; Michelle Goritzka; James Harker; Cecilia Johansson; Jacqueline U McDonald; Peter J M Openshaw
Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection.
Cindy L Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Peter Collins (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ruth A Karron; Elizabeth Schappell; Bhagvanji Thumar; Ursula J Buchholz; Peter L Collins
Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines.
The Journal of infectious diseases 2013;207(11):1773-9.
2013: John Tregoning; Belinda Lei Wang; Yuko Yamaguchi; Alexander Bukreyev; Peter L Collins; Michelle Goritzka; James Harker; Cecilia Johansson; Jacqueline U McDonald; Peter J M Openshaw
Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection.
Proceedings of the National Academy of Sciences of the United States of America 2013;110(14):5576-81.
2013: Cindy L Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.
Journal of virology 2013;87(4):1985-96.
2012: Anne Schaap-Nutt; Margaret A Scull; Emmalene J Bartlett; Peter L Collins; Rachael Liesman; Raymond J Pickles; Alexander C Schmidt
Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium.
Virology 2012;433(2):320-8.
2012: Alexander Bukreyev; Lijuan Yang; Peter L Collins
The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement.
Journal of virology 2012;86(19):10880-4.
2012: Cindy L Luongo; Christine C Winter; Peter L Collins; Ursula J Buchholz
Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.
Journal of virology 2012;86(19):10792-804.
2012: Ruth A Karron; Brian R Murphy; Elizabeth Schappell; Sonja R Surman; Bhagvanji Thumar; Peter L Collins; Alexander C Schmidt
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.
Vaccine 2012;30(26):3975-81.
2012: Henrick Schomacker; Peter L Collins; Anne Schaap-Nutt; Alexander C Schmidt
Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.
Current opinion in virology 2012;2(3):294-9.
2012: Linda G Brock; Peter L Collins; Ruth A Karron; Christine D Krempl; Ursula J Buchholz
Evaluation of pneumonia virus of mice as a possible human pathogen.
Journal of virology 2012;86(10):5829-43.
2012: Marcus L Hastie; Madeleine J Headlam; Emma L Norris; Nirav B Patel; Kirsten M Spann; Cassandra L Wright; Ursula J Buchholz; Alexander Bukreyev; Peter L Collins; Keyur A Dave; Jeffrey J Gorman
The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways.
Molecular & cellular proteomics : MCP 2012;11(5):108-27.
2012: Henrick Schomacker; Sonja R Surman; Emerito Amaro-Carambot; Jim Boonyaratanakornkit; Peter L Collins; Rebecca M Hebner; Alexander C Schmidt
The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome.
PloS one 2012;7(2):e28382.
2011: Liqun Zhang; Peter L Collins; Robert A Lamb; Raymond J Pickles
Comparison of differing cytopathic effects in human airway epithelium of parainfluenza virus 5 (W3A), parainfluenza virus type 3, and respiratory syncytial virus.
Virology 2011;421(1):67-77.
2011: Peter L Collins; José A Melero
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.
Virus research 2011;162(1-2):80-99.
2011: Ruth A Karron; Brian R Murphy; Roberta Casey; Peter L Collins; Sonja R Surman; Bhagvanji Thumar; Alexander C Schmidt
The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.
The Pediatric infectious disease journal 2011;30(10):e186-91.
2011: Alexander C Schmidt; Henrick Schomacker; Emmalene J Bartlett; Jim Boonyaratanakornkit; Ruth A Karron; Anne Schaap-Nutt; Peter L Collins
Progress in the development of human parainfluenza virus vaccines.
Expert review of respiratory medicine 2011;5(4):515-26.
2011: Cyril Le Nouën; Thomas McCarty; Ronald L Rabin; Christine C Winter; Peter L Collins; Philippa Hillyer; Ursula J Buchholz
Low CCR7-mediated migration of human monocyte derived dendritic cells in response to human respiratory syncytial virus and human metapneumovirus.
PLoS pathogens 2011;7(6):e1002105.
2011: Shirin Munir; Philippa Hillyer; Cyril Le Nouën; Ursula J Buchholz; Ronald L Rabin; Peter L Collins; Alexander Bukreyev
Respiratory syncytial virus interferon antagonist NS1 protein suppresses and skews the human T lymphocyte response.
PLoS pathogens 2011;7(4):e1001336.
2011: Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.
Journal of virology 2011;85(8):4007-19.
2010: Joshua M DiNapoli; Lijuan Yang; Siba K. Samal; Brian R Murphy; Peter L Collins; Alexander Bukreyev
Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
Vaccine 2010;29(1):17-25.
2010: Liqun Zhang; Maria P Limberis; Catherine Thompson; Marcelo B Antunes; Cindy Luongo; James M Wilson; Peter L Collins; Raymond J Pickles
α-Fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors.
Human gene therapy 2010;21(12):1657-64.
2010: Anne Schaap-Nutt; Christopher D'Angelo; Emerito Amaro-Carambot; Sheila M Nolan; Stephanie Davis; Shenelle-Marie Wise; Caraline Higgins; Konrad Bradley; Olivia Kim; Reina Mayor; Mario H Skiadopoulos; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.
Virology 2010;406(1):65-79.
2010: Alexander Bukreyev; Joshua M Dinapoli; Lijuan Yang; Brian R Murphy; Peter L Collins
Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.
Virology 2010;399(2):290-8.
2010: James Harker; Alexandra Godlee; Jennifer L Wahlsten; Debbie C P Lee; Lucy G Thorne; Devika Sawant; John Tregoning; Rachel R Caspi; Alexander Bukreyev; Peter L Collins; Peter J M Openshaw
Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells.
Journal of virology 2010;84(8):4073-82.
2010: Anne Schaap-Nutt; Christopher D'Angelo; Margaret A Scull; Emerito Amaro-Carambot; Machiko Nishio; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.
Virology 2010;397(2):285-98.
2010: Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K. Samal; Peter L Collins; Alexander Bukreyev
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.
Journal of virology 2010;84(3):1489-503.
2010: Emmalene J Bartlett; Ann-Marie Cruz; Jim Boonyaratanakornkit; Janice Esker; Adam Castaño; Mario Skiadopoulos; Peter L Collins; Brian R Murphy; Alexander C Schmidt
A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.
Vaccine 2010;28(3):767-79.
2010: Cyril Le Nouën; Philippa Hillyer; Shirin Munir; Christine C Winter; Thomas McCarty; Alexander Bukreyev; Peter L Collins; Ronald L Rabin; Ursula J Buchholz
Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells.
PloS one 2010;5(11):e15017.
2009: Cindy L Luongo; Lijuan Yang; Christine C Winter; Kirsten M Spann; Brian Murphy; Peter L Collins; Ursula J Buchholz
Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.
Vaccine 2009;27(41):5667-76.
2009: Liqun Zhang; Brian Button; Sherif E Gabriel; Susan Burkett; Yu Yan; Mario Skiadopoulos; Yan Li Dang; Leatrice N Vogel; Tristan McKay; April Mengos; Richard C Boucher; Peter L Collins; Raymond J Pickles
CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.
PLoS biology 2009;7(7):e1000155.
2009: Martin L Moore; Michael H Chi; Cindy Luongo; Nicholas W Lukacs; Vasiliy V Polosukhin; Matthew M Huckabee; Dawn C Newcomb; Ursula J Buchholz; James Crowe; Kasia Goleniewska; John V Williams; Peter L Collins; R Stokes Peebles
A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.
Journal of virology 2009;83(9):4185-94.
2009: Joshua M DiNapoli; Jerrold M Ward; Lily Cheng; Lijuan Yang; Subbiah Elankumaran; Brian Murphy; Siba K. Samal; Peter L Collins; Alexander Bukreyev
Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.
Vaccine 2009;27(10):1530-9.
2009: Cyril Le Nouën; Shirin Munir; Stéphanie Losq; Christine C Winter; Thomas McCarty; David A Stephany; Kevin L Holmes; Alexander Bukreyev; Ronald L Rabin; Peter L Collins; Ursula J Buchholz
Infection and maturation of monocyte-derived human dendritic cells by human respiratory syncytial virus, human metapneumovirus, and human parainfluenza virus type 3.
Virology 2009;385(1):169-82.
2009: Ursula J Buchholz; Jerrold M Ward; Elaine W Lamirande; Britta Heinze; Christine D Krempl; Peter L Collins
Deletion of nonstructural proteins NS1 and NS2 from pneumonia virus of mice attenuates viral replication and reduces pulmonary cytokine expression and disease.
Journal of virology 2009;83(4):1969-80.
2009: Jim B Boonyaratanakornkit; Emmalene J Bartlett; Emerito Amaro-Carambot; Peter L Collins; Brian Murphy; Alexander C Schmidt
The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection.
Journal of virology 2009;83(4):1892-910.
2009: Alexander Bukreyev; Andrea Marzi; Friederike Feldmann; Liqun Zhang; Lijuan Yang; Jerrold M Ward; David W Dorward; Raymond J Pickles; Brian Murphy; Heinz Feldmann; Peter L Collins
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge.
Virology 2009;383(2):348-61.
2008: Alexander Bukreyev; Lijuan Yang; Jens Fricke; Lily Cheng; Jerrold M Ward; Brian Murphy; Peter L Collins
The secreted form of respiratory syncytial virus G glycoprotein helps the virus evade antibody-mediated restriction of replication by acting as an antigen decoy and through effects on Fc receptor-bearing leukocytes.
Journal of virology 2008;82(24):12191-204.
2008: Emmalene J Bartlett; Ann-Marie Cruz; Janice Esker; Adam Castaño; Henrick Schomacker; Sonja R Surman; Margaret Hennessey; Jim Boonyaratanakornkit; Raymond J Pickles; Peter L Collins; Brian Murphy; Alexander C Schmidt
Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.
Journal of virology 2008;82(18):8965-77.
2008: Shirin Munir; Cyril Le Nouen; Cindy L Luongo; Ursula J Buchholz; Peter L Collins; Alexander Bukreyev
Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells.
Journal of virology 2008;82(17):8780-96.
2008: Lijuan Yang; Anthony Sanchez; Jerrold M Ward; Brian Murphy; Peter L Collins; Alexander Bukreyev
A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
Virology 2008;377(2):255-64.
2008: Emmalene J Bartlett; Margaret Hennessey; Mario Skiadopoulos; Alexander C Schmidt; Peter L Collins; Brian Murphy; Raymond J Pickles
Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.
Journal of virology 2008;82(16):8059-70.
2008: Peter L Collins; Barney S Graham
Viral and host factors in human respiratory syncytial virus pathogenesis.
Journal of virology 2008;82(5):2040-55.
2008: Alexander Bukreyev; Peter L Collins
Newcastle disease virus as a vaccine vector for humans.
Current opinion in molecular therapeutics 2008;10(1):46-55.
2008: Joshua M DiNapoli; Brian Murphy; Peter L Collins; Alexander Bukreyev
Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection.
Virology journal 2008;5():105.
2007: James Harker; Alexander Bukreyev; Peter L Collins; Belinda Wang; Peter J M Openshaw; John Tregoning
Virally delivered cytokines alter the immune response to future lung infections.
Journal of virology 2007;81(23):13105-11.
2007: Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian Murphy; Siba K. Samal; Peter L Collins; Alexander Bukreyev
Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.
Journal of virology 2007;81(21):11560-8.
2007: Peter F Wright; Ruth A Karron; Robert B Belshe; Jian R Shi; Valerie B Randolph; Peter L Collins; Alice F O'Shea; William C Gruber; Brian Murphy
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines.
Vaccine 2007;25(42):7372-8.
2007: Guillermina A Melendi; Fidel Zavala; Ursula J Buchholz; Guy Boivin; Peter L Collins; Steven R Kleeberger; Fernando P Polack
Mapping and characterization of the primary and anamnestic H-2(d)-restricted cytotoxic T-lymphocyte response in mice against human metapneumovirus.
Journal of virology 2007;81(20):11461-7.
2007: Christine D Krempl; Anna Wnekowicz; Elaine W Lamirande; Giw Nayebagha; Peter L Collins; Ursula J Buchholz
Identification of a novel virulence factor in recombinant pneumonia virus of mice.
Journal of virology 2007;81(17):9490-501.
2007: Sheila M Nolan; Mario Skiadopoulos; Konrad Bradley; Olivia S Kim; Stacia Bier; Emerito Amaro-Carambot; Sonja R Surman; Stephanie Davis; Marisa St Claire; Randy Elkins; Peter L Collins; Brian Murphy; Anne Schaap-Nutt
Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
Vaccine 2007;25(34):6409-22.
2007: Joshua M DiNapoli; Alexander Kotelkin; Lijuan Yang; Subbiah Elankumaran; Brian Murphy; Siba K. Samal; Peter L Collins; Alexander Bukreyev
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(23):9788-93.
2007: Alexander Bukreyev; Pierre E Rollin; Mallory K Tate; Lijuan Yang; Sherif R Zaki; Wun-Ju Shieh; Brian Murphy; Peter L Collins; Anthony Sanchez
Successful topical respiratory tract immunization of primates against Ebola virus.
Journal of virology 2007;81(12):6379-88.
2007: stephane biacchesi; Brian Murphy; Peter L Collins; Ursula J Buchholz
Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro.
Journal of virology 2007;81(11):6057-67.
2007: Sonja R Surman; Peter L Collins; Brian Murphy; Mario Skiadopoulos
An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.
Journal of virological methods 2007;141(1):30-3.
2007: Emmalene J Bartlett; Adam Castaño; Sonja R Surman; Peter L Collins; Mario Skiadopoulos; Brian Murphy
Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
Virology journal 2007;4():67.
2006: Alexander Bukreyev; Mario Skiadopoulos; Brian Murphy; Peter L Collins
Nonsegmented negative-strand viruses as vaccine vectors.
Journal of virology 2006;80(21):10293-306.
2006: Ursula J Buchholz; Kunio Nagashima; Brian Murphy; Peter L Collins
Live vaccines for human metapneumovirus designed by reverse genetics.
Expert review of vaccines 2006;5(5):695-706.
2006: William Van Cleve; Emerito Amaro-Carambot; Sonja R Surman; Joseph Bekisz; Peter L Collins; Kathy Zoon; Brian Murphy; Mario Skiadopoulos; Emmalene J Bartlett
Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.
Virology 2006;352(1):61-73.
2006: Alexander Kotelkin; Igor M Belyakov; Lijuan Yang; Jay A Berzofsky; Peter L Collins; Alexander Bukreyev
The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response.
Journal of virology 2006;80(12):5958-67.
2006: Alexander Bukreyev; Maria Elina Serra; Federico R Laham; Guillermina A Melendi; Steven R Kleeberger; Peter L Collins; Fernando P Polack
The cysteine-rich region and secreted form of the attachment G glycoprotein of respiratory syncytial virus enhance the cytotoxic T-lymphocyte response despite lacking major histocompatibility complex class I-restricted epitopes.
Journal of virology 2006;80(12):5854-61.
2006: stephane biacchesi; Quynh N Pham; Mario Skiadopoulos; Brian Murphy; Peter L Collins; Ursula J Buchholz
Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates.
Journal of virology 2006;80(12):5798-806.
2006: Bo Chi; Harold Dickensheets; Kirsten M Spann; Marc A Alston; Cindy Luongo; Laure Dumoutier; Jiaying Huang; Jean-Christophe Renauld; Sergei V Kotenko; Mario Roederer; Judy A Beeler; Raymond P Donnelly; Peter L Collins; Ronald L Rabin
Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus.
Journal of virology 2006;80(10):5032-40.
2006: Emmalene J Bartlett; Emerito Amaro-Carambot; Sonja R Surman; Peter L Collins; Brian Murphy; Mario Skiadopoulos
Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.
Vaccine 2006;24(14):2674-84.
2006: Alexander Bukreyev; Lijuan Yang; Sherif R Zaki; Wun-Ju Shieh; Pierre E Rollin; Brian Murphy; Peter L Collins; Anthony Sanchez
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
Journal of virology 2006;80(5):2267-79.
2006: Mario Skiadopoulos; stephane biacchesi; Ursula J Buchholz; Emerito Amaro-Carambot; Sonja R Surman; Peter L Collins; Brian Murphy
Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.
Virology 2006;345(2):492-501.
2006: Peter F Wright; Ruth A Karron; Shabir A Madhi; John J Treanor; James C King; Alice O'Shea; Mine R Ikizler; Yuwei Zhu; Peter L Collins; Clare Cutland; Valerie B Randolph; Anne M Deatly; Jill Hackell; William C Gruber; Brian Murphy
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans.
The Journal of infectious diseases 2006;193(4):573-81.
2005: Amy C Sims; Ralph S Baric; Boyd Yount; Susan E Burkett; Peter L Collins; Raymond J Pickles
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs.
Journal of virology 2005;79(24):15511-24.
2005: Quynh N Pham; stephane biacchesi; Mario Skiadopoulos; Brian Murphy; Peter L Collins; Ursula J Buchholz
Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo.
Journal of virology 2005;79(24):15114-22.
2005: Alexander Bukreyev; Zhuhui Huang; Lijuan Yang; Subbiah Elankumaran; Marisa St Claire; Brian Murphy; Siba K. Samal; Peter L Collins
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Journal of virology 2005;79(21):13275-84.
2005: Robert Tarran; Brian Button; Maryse Picher; Anthony M Paradiso; Carla M Pedrosa Ribeiro; Eduardo R Lazarowski; Liqun Zhang; Peter L Collins; Raymond J Pickles; Jeffrey J Fredberg; Richard C Boucher
Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections.
The Journal of biological chemistry 2005;280(42):35751-9.
2005: stephane biacchesi; Quynh N Pham; Mario Skiadopoulos; Brian Murphy; Peter L Collins; Ursula J Buchholz
Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates.
Journal of virology 2005;79(19):12608-13.
2005: Sheila M Nolan; Sonja R Surman; Emerito Amaro-Carambot; Peter L Collins; Brian Murphy; Mario Skiadopoulos
Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses.
Vaccine 2005;23(39):4765-74.
2005: Emmalene J Bartlett; Emerito Amaro-Carambot; Sonja R Surman; Jason T Newman; Peter L Collins; Brian Murphy; Mario Skiadopoulos
Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
Vaccine 2005;23(38):4631-46.
2005: stephane biacchesi; Mario Skiadopoulos; Lijuan Yang; Brian Murphy; Peter L Collins; Ursula J Buchholz
Rapid human metapneumovirus microneutralization assay based on green fluorescent protein expression.
Journal of virological methods 2005;128(1-2):192-7.
2005: Alexander Bukreyev; Igor M Belyakov; Gregory A Prince; Kevin Yim; Katie K Harris; Jay A Berzofsky; Peter L Collins
Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
Journal of virology 2005;79(15):9515-26.
2005: Fernando P Polack; Pablo M Irusta; S Hoffman; M Paula Schiatti; Guillermina A Melendi; M Florencia Delgado; Federico R Laham; Bhagvanji Thumar; R Michael Hendry; Jose A Melero; Ruth A Karron; Peter L Collins; Steven R Kleeberger
The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(25):8996-9001.
2005: Ursula J Buchholz; stephane biacchesi; Quynh N Pham; Kim C Tran; Lijuan Yang; Cindy L Luongo; Mario Skiadopoulos; Brian Murphy; Peter L Collins
Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity.
Journal of virology 2005;79(11):6588-97.
2005: Kirsten M Spann; Kim C Tran; Peter L Collins
Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines.
Journal of virology 2005;79(9):5353-62.
2005: tara gower; Manoj K Pastey; Mark Peeples; Peter L Collins; Lewis H McCurdy; Timothy K Hart; Alex Guth; Teresa Johnson; Barney S Graham
RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology.
Journal of virology 2005;79(9):5326-36.
2005: Ruth A Karron; Peter F Wright; Robert B Belshe; Bhagvanji Thumar; Roberta Casey; Frances K Newman; Fernando P Polack; Valerie B Randolph; Anne M Deatly; Jill Hackell; William C Gruber; Brian Murphy; Peter L Collins
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
The Journal of infectious diseases 2005;191(7):1093-104.
2005: Christine D Krempl; Elaine W Lamirande; Peter L Collins
Complete sequence of the RNA genome of pneumonia virus of mice (PVM).
Virus genes 2005;30(2):237-49.
2005: Peter L Collins; Brian Murphy
New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.
Proceedings of the American Thoracic Society 2005;2(2):166-73.
2005: Liqun Zhang; Alexander Bukreyev; Catherine I Thompson; Brandy Watson; Mark Peeples; Peter L Collins; Raymond J Pickles
Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.
Journal of virology 2005;79(2):1113-24.
2004: Christine D Krempl; Peter L Collins
Reevaluation of the virulence of prototypic strain 15 of pneumonia virus of mice.
Journal of virology 2004;78(23):13362-5.
2004: stephane biacchesi; Mario Skiadopoulos; Lijuan Yang; Elaine W Lamirande; Kim C Tran; Brian Murphy; Peter L Collins; Ursula J Buchholz
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate.
Journal of virology 2004;78(23):12877-87.
2004: Mario Skiadopoulos; stephane biacchesi; Ursula J Buchholz; Jeffrey M Riggs; Sonja R Surman; Emerito Amaro-Carambot; Josephine McAuliffe; William R Elkins; Marisa St Claire; Peter L Collins; Brian Murphy
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.
Journal of virology 2004;78(13):6927-37.
2004: Ursula J Buchholz; Alexander Bukreyev; Lijuan Yang; Elaine W Lamirande; Brian Murphy; Kanta Subbarao; Peter L Collins
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(26):9804-9.
2004: Alexander Bukreyev; Elaine W Lamirande; Ursula J Buchholz; Leatrice N Vogel; William R Elkins; Marisa St Claire; Brian Murphy; Kanta Subbarao; Peter L Collins
Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
Lancet 2004;363(9427):2122-7.
2004: Himani Bisht; Anjeanette Roberts; Leatrice Vogel; Alexander Bukreyev; Peter L Collins; Brian Murphy; Kanta Subbarao; Bernard Moss
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(17):6641-6.
2004: stephane biacchesi; Mario Skiadopoulos; Kim C Tran; Brian Murphy; Peter L Collins; Ursula J Buchholz
Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes.
Virology 2004;321(2):247-59.
2004: Kirsten M Spann; Kim C Tran; Bo Chi; Ronald L Rabin; Peter L Collins
Suppression of the induction of alpha, beta, and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages [corrected].
Journal of virology 2004;78(8):4363-9.
2004: Josephine McAuliffe; Sonja R Surman; Jason T Newman; Jeffrey M Riggs; Peter L Collins; Brian Murphy; Mario Skiadopoulos
Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
Journal of virology 2004;78(4):2029-36.
2004: Jason T Newman; Jeffrey M Riggs; Sonja R Surman; Josephine McAuliffe; Teresa A Mulaikal; Peter L Collins; Brian Murphy; Mario Skiadopoulos
Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
Journal of virology 2004;78(4):2017-28.
2004: Kim C Tran; Peter L Collins; Michael N Teng
Effects of altering the transcription termination signals of respiratory syncytial virus on viral gene expression and growth in vitro and in vivo.
Journal of virology 2004;78(2):692-9.
2003: stephane biacchesi; Mario Skiadopoulos; Guy Boivin; Christopher T Hanson; Brian Murphy; Peter L Collins; Ursula J Buchholz
Genetic diversity between human metapneumovirus subgroups.
Virology 2003;315(1):1-9.
2003: Kirsten M Spann; Peter L Collins; Michael N Teng
Genetic recombination during coinfection of two mutants of human respiratory syncytial virus.
Journal of virology 2003;77(20):11201-11.
2003: Alexander Kotelkin; Elena A Prikhod'ko; Jeffrey I Cohen; Peter L Collins; Alexander Bukreyev
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand.
Journal of virology 2003;77(17):9156-72.
2003: Mario Skiadopoulos; Alexander C Schmidt; Jeffrey M Riggs; Sonja R Surman; William R Elkins; Marisa St Claire; Peter L Collins; Brian Murphy
Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.
Journal of virology 2003;77(2):1141-8.
2003: Mario Skiadopoulos; Leatrice Vogel; Jeffrey M Riggs; Sonja R Surman; Peter L Collins; Brian Murphy
The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.
Journal of virology 2003;77(1):270-9.
2002: Alexander Bukreyev; Mario Skiadopoulos; Josephine McAuliffe; Brian Murphy; Peter L Collins; Alexander C Schmidt
More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?
Proceedings of the National Academy of Sciences of the United States of America 2002;99(26):16987-91.
2002: Christine Krempl; Brian Murphy; Peter L Collins
Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions.
Journal of virology 2002;76(23):11931-42.
2002: Fernando P Polack; Michael N Teng; Peter L Collins; Gregory A Prince; Marcus Exner; Heinz Regele; Dario D Lirman; Richard Rabold; S Hoffman; Christopher L Karp; Steven R Kleeberger; MARSHA WILLS-KARP; Ruth A Karron
A role for immune complexes in enhanced respiratory syncytial virus disease.
The Journal of experimental medicine 2002;196(6):859-65.
2002: Brian Murphy; Peter L Collins
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics.
The Journal of clinical investigation 2002;110(1):21-7.
2002: Michael N Teng; Peter L Collins
The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.
Journal of virology 2002;76(12):6164-71.
2002: Liqun Zhang; Mark Peeples; Richard C Boucher; Peter L Collins; Raymond J Pickles
Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology.
Journal of virology 2002;76(11):5654-66.
2002: Mario Skiadopoulos; Sonja R Surman; Jeffrey M Riggs; William R Elkins; Marisa St Claire; Machiko Nishio; Dominique Garcin; Daniel Kolakofsky; Peter L Collins; Brian Murphy
Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.
Virology 2002;297(1):153-60.
2002: Mario Skiadopoulos; Sonja R Surman; Jeffrey M Riggs; Claes Orvell; Peter L Collins; Brian Murphy
Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.
Virology 2002;297(1):136-52.
2002: Peter L Collins; Brian Murphy
Respiratory syncytial virus: reverse genetics and vaccine strategies.
Virology 2002;296(2):204-11.
2002: Sunee Techaarpornkul; Peter L Collins; Mark Peeples
Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.
Virology 2002;294(2):296-304.
2002: Rachel Fearns; Mark Peeples; Peter L Collins
Mapping the transcription and replication promoters of respiratory syncytial virus.
Journal of virology 2002;76(4):1663-72.
2002: Alexander C Schmidt; Daniel R Wenzke; Josephine McAuliffe; Marisa St Claire; William R Elkins; Brian Murphy; Peter L Collins
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.
Journal of virology 2002;76(3):1089-99.
2002: Jason T Newman; Sonja R Surman; Jeffrey M Riggs; Chris T Hansen; Peter L Collins; Brian Murphy; Mario Skiadopoulos
Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.
Virus genes 2002;24(1):77-92.
2001: Alexander Bukreyev; Igor M Belyakov; Jay A Berzofsky; Brian Murphy; Peter L Collins
Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.
Journal of virology 2001;75(24):12128-40.
2001: Mario Skiadopoulos; Sonja R Surman; Jeffrey M Riggs; Peter L Collins; Brian Murphy
A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys.
Journal of virology 2001;75(21):10498-504.
2001: Michael N Teng; Stephen S Whitehead; Peter L Collins
Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.
Virology 2001;289(2):283-96.
2001: K A Sutherland; Peter L Collins; Mark Peeples
Synergistic effects of gene-end signal mutations and the M2-1 protein on transcription termination by respiratory syncytial virus.
Virology 2001;288(2):295-307.
2001: T Tao; Mario Skiadopoulos; F Davoodi; Sonja R Surman; Peter L Collins; Brian Murphy
Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.
Vaccine 2001;19(27):3620-31.
2001: tara gower; Mark Peeples; Peter L Collins; Barney S Graham
RhoA is activated during respiratory syncytial virus infection.
Virology 2001;283(2):188-96.
2001: Alexander C Schmidt; Josephine McAuliffe; Brian Murphy; Peter L Collins
Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
Journal of virology 2001;75(10):4594-603.
2000: Alexander Bukreyev; Brian Murphy; Peter L Collins
Respiratory syncytial virus can tolerate an intergenic sequence of at least 160 nucleotides with little effect on transcription or replication in vitro and in vivo.
Journal of virology 2000;74(23):11017-26.
2000: Louay K Hallak; D Spillmann; Peter L Collins; Mark Peeples
Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.
Journal of virology 2000;74(22):10508-13.
2000: Michael N Teng; Stephen S Whitehead; Alison Bermingham; Marisa St Claire; William R Elkins; Brian Murphy; Peter L Collins
Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees.
Journal of virology 2000;74(19):9317-21.
2000: Alexander C Schmidt; Josephine McAuliffe; A Huang; Sonja R Surman; JE Bailly; William R Elkins; Peter L Collins; Brian Murphy; Mario Skiadopoulos
Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.
Journal of virology 2000;74(19):8922-9.
2000: Alexander Bukreyev; Stephen S Whitehead; C Prussin; Brian Murphy; Peter L Collins
Effect of coexpression of interleukin-2 by recombinant respiratory syncytial virus on virus replication, immunogenicity, and production of other cytokines.
Journal of virology 2000;74(15):7151-7.
2000: Anna P Durbin; Mario Skiadopoulos; Josephine McAuliffe; Jeffrey M Riggs; Sonja R Surman; Peter L Collins; Brian Murphy
Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.
Journal of virology 2000;74(15):6821-31.
2000: T Tao; Mario Skiadopoulos; F Davoodi; Jeffrey M Riggs; Peter L Collins; Brian Murphy
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
Journal of virology 2000;74(14):6448-58.
2000: Rachel Fearns; Peter L Collins; Mark Peeples
Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus.
Journal of virology 2000;74(13):6006-14.
2000: Mario Skiadopoulos; Sonja R Surman; Anna P Durbin; Peter L Collins; Brian Murphy
Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
Virology 2000;272(1):225-34.
2000: Louay K Hallak; Peter L Collins; W Knudson; Mark Peeples
Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.
Virology 2000;271(2):264-75.
2000: JE Bailly; Josephine McAuliffe; Anna P Durbin; William R Elkins; Peter L Collins; Brian Murphy
A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.
Journal of virology 2000;74(7):3188-95.
2000: Ursula J Buchholz; Harald Granzow; K Schuldt; S S Whitehead; Brian Murphy; Peter L Collins
Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.
Journal of virology 2000;74(3):1187-99.
2000: T Tao; F Davoodi; C J Cho; Mario Skiadopoulos; Anna P Durbin; Peter L Collins; Brian Murphy
A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Vaccine 2000;18(14):1359-66.
2000: JE Bailly; Josephine McAuliffe; Mario Skiadopoulos; Peter L Collins; Brian Murphy
Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.
Virus genes 2000;20(2):173-82.
2000: Mark Peeples; Peter L Collins
Mutations in the 5' trailer region of a respiratory syncytial virus minigenome which limit RNA replication to one step.
Journal of virology 2000;74(1):146-55.
1999: Stephen S Whitehead; M G Hill; Cai-Yen Firestone; Marisa St Claire; William R Elkins; Brian Murphy; Peter L Collins
Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
Journal of virology 1999;73(12):9773-80.
1999: Mario Skiadopoulos; T Tao; Sonja R Surman; Peter L Collins; Brian Murphy
Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts.
Vaccine 1999;18(5-6):503-10.
1999: Alison Bermingham; Peter L Collins
The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(20):11259-64.
1999: Anna P Durbin; Josephine McAuliffe; Peter L Collins; Brian Murphy
Mutations in the C, D, and V open reading frames of human parainfluenza virus type 3 attenuate replication in rodents and primates.
Virology 1999;261(2):319-30.
1999: Mario Skiadopoulos; Sonja R Surman; Marisa St Claire; William R Elkins; Peter L Collins; Brian Murphy
Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
Virology 1999;260(1):125-35.
1999: Peter L Collins; E Camargo; M G Hill
Support plasmids and support proteins required for recovery of recombinant respiratory syncytial virus.
Virology 1999;259(2):251-5.
1999: Rachel Fearns; Peter L Collins
Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription.
Journal of virology 1999;73(7):5852-64.
1999: K Juhasz; Brian Murphy; Peter L Collins
The major attenuating mutations of the respiratory syncytial virus vaccine candidate cpts530/1009 specify temperature-sensitive defects in transcription and replication and a non-temperature-sensitive alteration in mRNA termination.
Journal of virology 1999;73(6):5176-80.
1999: Stephen S Whitehead; Alexander Bukreyev; Michael N Teng; Cai-Yen Firestone; Marisa St Claire; William R Elkins; Peter L Collins; Brian Murphy
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.
Journal of virology 1999;73(4):3438-42.
1999: K Juhasz; Stephen S Whitehead; C A Boulanger; Cai-Yen Firestone; Peter L Collins; Brian Murphy
The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations.
Vaccine 1999;17(11-12):1416-24.
1999: T Tao; Mario Skiadopoulos; Anna P Durbin; F Davoodi; Peter L Collins; Brian Murphy
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Vaccine 1999;17(9-10):1100-8.
1999: Alexander Bukreyev; Stephen S Whitehead; N Bukreyeva; Brian Murphy; Peter L Collins
Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(5):2367-72.
1999: Mario Skiadopoulos; Sonja R Surman; Joanne M Tatem; Maribel Paschalis; Shin-Lu Wu; S A Udem; Anna P Durbin; Peter L Collins; Brian Murphy
Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
Journal of virology 1999;73(2):1374-81.
1999: Stephen S Whitehead; Cai-Yen Firestone; Ruth A Karron; James Crowe; William R Elkins; Peter L Collins; Brian Murphy
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
Journal of virology 1999;73(2):871-7.
1999: Peter L Collins; Stephen S Whitehead; Alexander Bukreyev; Rachel Fearns; Michael N Teng; K Juhasz; Robert M Chanock; Brian Murphy
Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics.
Advances in virus research 1999;54():423-51.
1999: Michael N Teng; Peter L Collins
Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein.
Journal of virology 1999;73(1):466-73.
1999: Rachel Fearns; Peter L Collins
Model for polymerase access to the overlapped L gene of respiratory syncytial virus.
Journal of virology 1999;73(1):388-97.
1998: Stephen S Whitehead; Cai-Yen Firestone; Peter L Collins; Brian Murphy
A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
Virology 1998;247(2):232-9.
1998: Michael N Teng; Peter L Collins
Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles.
Journal of virology 1998;72(7):5707-16.
1998: Stephen S Whitehead; K Juhasz; Cai-Yen Firestone; Peter L Collins; Brian Murphy
Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees.
Journal of virology 1998;72(5):4467-71.
1998: T Tao; Anna P Durbin; Stephen S Whitehead; F Davoodi; Peter L Collins; Brian Murphy
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
Journal of virology 1998;72(4):2955-61.
1998: Mario Skiadopoulos; Anna P Durbin; Joanne M Tatem; Shin-Lu Wu; Maribel Paschalis; T Tao; Peter L Collins; Brian Murphy
Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
Journal of virology 1998;72(3):1762-8.
1998: P L Atreya; Mark Peeples; Peter L Collins
The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication.
Journal of virology 1998;72(2):1452-61.
1997: Alexander Bukreyev; Stephen S Whitehead; Brian Murphy; Peter L Collins
Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse.
Journal of virology 1997;71(12):8973-82.
1997: Rachel Fearns; Mark Peeples; Peter L Collins
Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome.
Virology 1997;236(1):188-201.
1997: Anna P Durbin; S L Hall; JW Siew; Stephen S Whitehead; Peter L Collins; Brian Murphy
Recovery of infectious human parainfluenza virus type 3 from cDNA.
Virology 1997;235(2):323-32.
1997: K Juhasz; Stephen S Whitehead; P T Bui; J M Biggs; James Crowe; C A Boulanger; Peter L Collins; Brian Murphy
The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein.
Journal of virology 1997;71(8):5814-9.
1997: Anna P Durbin; JW Siew; Brian Murphy; Peter L Collins
Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six.
Virology 1997;234(1):74-83.
1997: L Kuo; Rachel Fearns; Peter L Collins
Analysis of the gene start and gene end signals of human respiratory syncytial virus: quasi-templated initiation at position 1 of the encoded mRNA.
Journal of virology 1997;71(7):4944-53.
1997: Brian Murphy; Peter L Collins
Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting.
Bulletin of the World Health Organization 1997;75(4):307-13.
1996: Cai-Yen Firestone; Stephen S Whitehead; Peter L Collins; Brian Murphy; James Crowe
Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.
Virology 1996;225(2):419-22.
1996: L Kuo; H Grosfeld; J Cristina; M G Hill; Peter L Collins
Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus.
Journal of virology 1996;70(10):6892-901.
1996: Alexander Bukreyev; E Camargo; Peter L Collins
Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene.
Journal of virology 1996;70(10):6634-41.
1996: L Kuo; Rachel Fearns; Peter L Collins
The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome.
Journal of virology 1996;70(9):6143-50.
1996: Peter L Collins; M G Hill; J Cristina; H Grosfeld
Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(1):81-5.
1996: James Crowe; Cai-Yen Firestone; Stephen S Whitehead; Peter L Collins; Brian Murphy
Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene.
Virus genes 1996;13(3):269-73.
1995: Peter L Collins; M G Hill; E Camargo; H Grosfeld; Robert M Chanock; Brian Murphy
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(25):11563-7.
1995: H Grosfeld; M G Hill; Peter L Collins
RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.
Journal of virology 1995;69(9):5677-86.
1995: M Connors; James Crowe; Cai-Yen Firestone; Brian Murphy; Peter L Collins
A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes.
Virology 1995;208(2):478-84.
1995: A B Kulkarni; Peter L Collins; Igor Bacik; jon yewdell; Jack R Bennink; James Crowe; Brian Murphy
Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus.
Journal of virology 1995;69(2):1261-4.
1994: Brian Murphy; S L Hall; A B Kulkarni; James Crowe; Peter L Collins; M Connors; Ruth A Karron; Robert M Chanock
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.
Virus research 1994;32(1):13-36.
1993: James Crowe; Peter L Collins; W T London; Robert M Chanock; Brian Murphy
A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.
Vaccine 1993;11(14):1395-404.
1993: Peter L Collins; G Mottet
Membrane orientation and oligomerization of the small hydrophobic protein of human respiratory syncytial virus.
The Journal of general virology 1993;74 ( Pt 7)():1445-50.
1993: Peter L Collins; M A Mink; M G Hill; E Camargo; H Grosfeld; D S Stec
Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNA.
Virology 1993;195(1):252-6.
1993: K Dimock; Peter L Collins
Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3.
Journal of virology 1993;67(5):2772-8.
1993: A Martin-Gallardo; E Fleischer; S A Doyle; R Arumugham; Peter L Collins; S W Hildreth; Peter Paradiso
Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium.
The Journal of general virology 1993;74 ( Pt 3)():453-8.
1992: Robert M Chanock; R H Parrott; M Connors; Peter L Collins; Brian Murphy
Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization.
Pediatrics 1992;90(1 Pt 2):137-43.
1992: M I Gorziglia; Peter L Collins
Intracellular amplification and expression of a synthetic analog of rotavirus genomic RNA bearing a foreign marker gene: mapping cis-acting nucleotides in the 3'-noncoding region.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(13):5784-8.
1992: Peter L Collins; G Mottet
Oligomerization and post-translational processing of glycoprotein G of human respiratory syncytial virus: altered O-glycosylation in the presence of brefeldin A.
The Journal of general virology 1992;73 ( Pt 4)():849-63.
1992: M Connors; A B Kulkarni; Peter L Collins; Cai-Yen Firestone; K L Holmes; Herbert C Morse; Brian Murphy
Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
Journal of virology 1992;66(2):1277-81.
1992: M Connors; Peter L Collins; Cai-Yen Firestone; A V Sotnikov; A Waitze; A R Davis; P P Hung; Robert M Chanock; Brian Murphy
Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
Vaccine 1992;10(7):475-84.
1991: M A Mink; D S Stec; Peter L Collins
Nucleotide sequences of the 3' leader and 5' trailer regions of human respiratory syncytial virus genomic RNA.
Virology 1991;185(2):615-24.
1991: Peter L Collins; G Mottet
Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus.
The Journal of general virology 1991;72 ( Pt 12)():3095-101.
1991: Peter L Collins; M A Mink; D S Stec
Rescue of synthetic analogs of respiratory syncytial virus genomic RNA and effect of truncations and mutations on the expression of a foreign reporter gene.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(21):9663-7.
1991: A Martin-Gallardo; K A Fien; B T Hu; J F Farley; R Seid; Peter L Collins; S W Hildreth; Peter Paradiso
Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope.
Virology 1991;184(1):428-32.
1991: D S Stec; M G Hill; Peter L Collins
Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses.
Virology 1991;183(1):273-87.
1991: Peter L Collins; G Mottet
Homooligomerization of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 occurs before the acquisition of correct intramolecular disulfide bonds and mature immunoreactivity.
Journal of virology 1991;65(5):2362-71.
1991: Brian Murphy; G A Prince; Peter L Collins; S W Hildreth; Peter Paradiso
Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
Vaccine 1991;9(3):185-9.
1991: M Connors; Peter L Collins; Cai-Yen Firestone; Brian Murphy
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
Journal of virology 1991;65(3):1634-7.
1990: Peter L Collins; M G Hill; P R Johnson
The two open reading frames of the 22K mRNA of human respiratory syncytial virus: sequence comparison of antigenic subgroups A and B and expression in vitro.
The Journal of general virology 1990;71 ( Pt 12)():3015-20.
1990: Peter L Collins
O glycosylation of glycoprotein G of human respiratory syncytial virus is specified within the divergent ectodomain.
Journal of virology 1990;64(8):4007-12.
1990: Peter L Collins; R A Olmsted; P R Johnson
The small hydrophobic protein of human respiratory syncytial virus: comparison between antigenic subgroups A and B.
The Journal of general virology 1990;71 ( Pt 7)():1571-6.
1990: M K Spriggs; Peter L Collins
Intracellular processing and transport of NH2-terminally truncated forms of a hemagglutinin-neuraminidase type II glycoprotein.
The Journal of cell biology 1990;111(1):31-44.
1990: Brian Murphy; G A Prince; L A Lawrence; K D Croen; Peter L Collins
Detection of respiratory syncytial virus (RSV) infected cells by in situ hybridization in the lungs of cotton rats immunized with formalin-inactivated virus or purified RSV F and G glycoprotein subunit vaccine and challenged with RSV.
Virus research 1990;16(2):153-62.
1990: Peter L Collins; Robert Purcell; W T London; L A Lawrence; Robert M Chanock; Brian Murphy
Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus.
Vaccine 1990;8(2):164-8.
1990: P R Johnson; Peter L Collins
Sequence comparison of the phosphoprotein mRNAs of antigenic subgroups A and B of human respiratory syncytial virus identifies a highly divergent domain in the predicted protein.
The Journal of general virology 1990;71 ( Pt 2)():481-5.
1989: Brian Murphy; Peter L Collins; L Lawrence; J Zubak; Robert M Chanock; G A Prince
Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants.
The Journal of general virology 1989;70 ( Pt 8)():2185-90.
1989: P R Johnson; Peter L Collins
The 1B (NS2), 1C (NS1) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSV genomic RNA.
The Journal of general virology 1989;70 ( Pt 6)():1539-47.
1989: R A Olmsted; Peter L Collins
The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species.
Journal of virology 1989;63(5):2019-29.
1989: R A Olmsted; Brian Murphy; L A Lawrence; N Elango; Bernard Moss; Peter L Collins
Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virus.
Journal of virology 1989;63(1):411-20.
1988: R A Olmsted; R M Buller; Peter L Collins; W T London; J A Beeler; G A Prince; Robert M Chanock; Brian Murphy
Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus.
Vaccine 1988;6(6):519-24.
1988: P R Johnson; Peter L Collins
The A and B subgroups of human respiratory syncytial virus: comparison of intergenic and gene-overlap sequences.
The Journal of general virology 1988;69 ( Pt 11)():2901-6.
1988: P R Johnson; Peter L Collins
The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness.
The Journal of general virology 1988;69 ( Pt 10)():2623-8.
1988: Brian Murphy; R A Olmsted; Peter L Collins; Robert M Chanock; G A Prince
Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
Journal of virology 1988;62(10):3907-10.
1988: Brian Murphy; G A Prince; Peter L Collins; K Van Wyke Coelingh; R A Olmsted; M K Spriggs; R H Parrott; H W Kim; C D Brandt; Robert M Chanock
Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
Virus research 1988;11(1):1-15.
1988: Robert M Chanock; Brian Murphy; Peter L Collins; K V Coelingh; R A Olmsted; M H Snyder; M K Spriggs; G A Prince; Bernard Moss; J Flores
Live viral vaccines for respiratory and enteric tract diseases.
Vaccine 1988;6(2):129-33.
1988: M K Spriggs; Peter L Collins; E Tierney; W T London; Brian Murphy
Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection.
Journal of virology 1988;62(4):1293-6.
1987: M K Spriggs; Brian Murphy; G A Prince; R A Olmsted; Peter L Collins
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity.
Journal of virology 1987;61(11):3416-23.
1987: P R Johnson; R A Olmsted; G A Prince; Brian Murphy; D W Alling; E E Walsh; Peter L Collins
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.
Journal of virology 1987;61(10):3163-6.
1987: K L van Wyke Coelingh; Brian Murphy; Peter L Collins; A M Lebacq-Verheyden; James F Battey
Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus.
Virology 1987;160(2):465-72.
1987: P R Johnson; M K Spriggs; R A Olmsted; Peter L Collins
The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(16):5625-9.
1987: Peter L Collins; R A Olmsted; M K Spriggs; P R Johnson; A J Buckler-White
Gene overlap and site-specific attenuation of transcription of the viral polymerase L gene of human respiratory syncytial virus.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(15):5134-8.
1986: R A Olmsted; N Elango; G A Prince; Brian Murphy; P R Johnson; Bernard Moss; Robert M Chanock; Peter L Collins
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(19):7462-6.
1986: M K Spriggs; R A Olmsted; S Venkatesan; J E Coligan; Peter L Collins
Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses.
Virology 1986;152(1):241-51.
1986: Peter L Collins; L E Dickens; A Buckler-White; R A Olmsted; M K Spriggs; E Camargo; K V Coelingh
Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(13):4594-8.